Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancerKenichi Sugihara, Toshiaki Watanabe, Michio Itabashi et al.|International Journal of Clinical Oncology|2011Cited by 713
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancerToshiaki Watanabe, Michio Itabashi, Yasuhiro Shimada et al.|International Journal of Clinical Oncology|2015Cited by 600
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal CancerJun Watanabe, Takayuki Yoshino, Atsuo Takashima et al.|JAMA|2023Cited by 255
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.Takayuki Yoshino, Kei Muro, Jun Watanabe et al.|Journal of Clinical Oncology|2022Cited by 69